Seven Eight Capital LP Buys Shares of 178,203 ADMA Biologics, Inc. (NASDAQ:ADMA)

Seven Eight Capital LP bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 178,203 shares of the biotechnology company’s stock, valued at approximately $1,992,000. Seven Eight Capital LP owned about 0.08% of ADMA Biologics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Viewpoint Capital Management LLC boosted its holdings in ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares in the last quarter. Quest Partners LLC acquired a new stake in ADMA Biologics in the second quarter worth about $29,000. Arizona State Retirement System boosted its holdings in ADMA Biologics by 4.5% in the second quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock worth $689,000 after acquiring an additional 2,645 shares in the last quarter. Eagle Asset Management Inc. boosted its holdings in ADMA Biologics by 20.2% in the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 4,367 shares in the last quarter. Finally, CWM LLC boosted its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ADMA. Cantor Fitzgerald raised their price target on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Mizuho raised their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright raised their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $15.50.

Insider Activity at ADMA Biologics

In related news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Trading Up 3.3 %

ADMA Biologics stock opened at $19.32 on Thursday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $19.75. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -966.00 and a beta of 0.61. The stock has a 50-day moving average price of $15.48 and a 200 day moving average price of $10.77.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue was up 78.4% compared to the same quarter last year. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.